Global Idiopathic Pulmonary Fibrosis 2016-2020
ReportsWeb.com published “Idiopathic Pulmonary Fibrosis Global Market” from its database. This report identifies the market in different segments such as industry, application and geography. Detailed competitive analysis has been included in this report.
(EMAILWIRE.COM, December 22, 2017 ) Idiopathic pulmonary fibrosis belongs to a group of lung diseases known as interstitial lung diseases. It affects people in the age group 50-70 years. Diagnosis is effected by the exclusion of other interstitial lung diseases. High-resolution computed tomography (CT) is often employed to confirm the presence of the disease. There is no permanent cure for this disease; therefore, treatment involves relieving underlying symptoms. Nintedanib and pirfenidone are the two approved drugs for the treatment of idiopathic pulmonary fibrosis. Corticosteroids and immunosuppressive drugs are also used for the treatment.
Publisher's analysts forecast the global idiopathic pulmonary fibrosis market to grow at a CAGR of 23.97% during the period 2016-2020.
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001236129/sample
Covered in this report
The report covers the present scenario and the growth prospects of the global idiopathic pulmonary fibrosis market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of idiopathic pulmonary fibrosis.
The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA
Publisher's report, Global Idiopathic Pulmonary Fibrosis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
- Baxter International
- Boehringer Ingelheim
- F.Hoffmann-La Roche
- Prometheus Laboratories
Inquire before Buying at http://www.reportsweb.com/inquiry&RW0001236129/buying
Other prominent vendors
- Afferent Pharmaceuticals
- Amgen
- Biogen
- Bristol-Myers Squibb
- Cipla
- FibroGen
- Gilead Sciences
- GlaxoSmithKline
- GNI Group
- Horizon Pharma
- ImmuneWorks
- MediciNova
- MedImmune (subsidiary of AstraZeneca)
- Novartis
- Pfizer
- Promedior
- ProMetic Life Sciences
- Sanofi
- Shionogi
- Zai Lab
Market driver
- Unmet medical need
- For a full, detailed list, view our report
Market challenge
- Lack of proper diagnosis
- For a full, detailed list, view our report
Market trend
- Patient assistance programs
- For a full, detailed list, view our report
For more information about this report: http://www.reportsweb.com/global-idiopathic-pulmonary-fibrosis-2016-2020
Publisher's analysts forecast the global idiopathic pulmonary fibrosis market to grow at a CAGR of 23.97% during the period 2016-2020.
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001236129/sample
Covered in this report
The report covers the present scenario and the growth prospects of the global idiopathic pulmonary fibrosis market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of idiopathic pulmonary fibrosis.
The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA
Publisher's report, Global Idiopathic Pulmonary Fibrosis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
- Baxter International
- Boehringer Ingelheim
- F.Hoffmann-La Roche
- Prometheus Laboratories
Inquire before Buying at http://www.reportsweb.com/inquiry&RW0001236129/buying
Other prominent vendors
- Afferent Pharmaceuticals
- Amgen
- Biogen
- Bristol-Myers Squibb
- Cipla
- FibroGen
- Gilead Sciences
- GlaxoSmithKline
- GNI Group
- Horizon Pharma
- ImmuneWorks
- MediciNova
- MedImmune (subsidiary of AstraZeneca)
- Novartis
- Pfizer
- Promedior
- ProMetic Life Sciences
- Sanofi
- Shionogi
- Zai Lab
Market driver
- Unmet medical need
- For a full, detailed list, view our report
Market challenge
- Lack of proper diagnosis
- For a full, detailed list, view our report
Market trend
- Patient assistance programs
- For a full, detailed list, view our report
For more information about this report: http://www.reportsweb.com/global-idiopathic-pulmonary-fibrosis-2016-2020
Contact Information:
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results